TLR4 and TLR9 polymorphisms are not associated with either rheumatoid arthritis or systemic lupus erythematosus in Mexican patients.
Ivan Sammir Aranda-UribeJuan Carlos López-VázquezRosa Elda Barbosa-CobosJulián Ramírez BelloPublished in: Molecular biology reports (2021)
Toll-like receptor (TLR)-mediated signaling pathways induce a proinflammatory microenvironment to eradicate pathogens. However, in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), TLRs can promote chronic inflammation. It has been shown that some TLR4 and TLR9 single nucleotide polymorphisms (SNPs) are risk factors for RA and SLE, but these findings have not been replicated in all populations; thus, results are inconclusive. We evaluated the TLR4 Asp299Gly, Thr399Ile, - 1892G/A SNPs, and the TLR9 Pro545Pro SNP to assess potential associations with RA and SLE in Mexican patients. This study included 474 patients with RA, 283 patients with SLE, and 424 healthy controls. We used a 5' nuclease allelic discrimination assay to genotype individuals for the four TLR4 and TLR9 polymorphisms. We found that the genotype or allelic frequencies of the TLR4 Asp299Gly, Thr399Ile, - 1892G/A, and TLR9 Pro545Pro polymorphisms were similar between patients and controls. We found no association under different genetic models. A haplotype analysis of TLR4 showed no association with either RA or SLE. We found no significant differences in the allelic or genotypic frequencies of TLR4 Asp299Gly, Thr399IIe, - 1892G/A, or TLR9 Pro545Pro between patients and controls. These findings suggested that these variants are not risk factors for RA or SLE in Mexican patients.
Keyphrases
- toll like receptor
- systemic lupus erythematosus
- rheumatoid arthritis
- inflammatory response
- disease activity
- immune response
- end stage renal disease
- nuclear factor
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- oxidative stress
- genome wide
- patient reported outcomes
- anti inflammatory
- epithelial mesenchymal transition
- multidrug resistant
- transcription factor
- systemic sclerosis